The plausible contribution of HO-1 in prevention of CVD, NASH, insulin resistance, inflammation, apoptosis, oxidation and adipogenesis provide insight into the importance of utilizing HO-1 and associated pathways in therapeutic regimens to reduce the morbidity and mortality associated with obesity phenotypes. The gene discussed is HMOX1; the disease is obesity due to melanocortin 4 receptor deficiency.